Nile Therapeutics begin Phase IIa with CD-NP in Heart Failure Patients « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Nile Therapeutics begin Phase IIa with CD-NP in Heart Failure Patients

Posted on July 16, 2008 by crimsoncanary

Nile Therapeutics have initiated a Phase IIa trial of its NPRb agonist CD-NP in acute setting heart failure patients.

Filed under: gpcr | Tagged: agonist, CD-NP, natriuretic peptide receptor B, Nile Therapeutics, nprb, phase II, Phase IIa

« Novo Nordisk submit new drug application for liraglutide in Japan Anesiva insitate Phase II trual of Adlea in Arthroscopic Shoulder Surgery »

Leave a Reply